The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Targeted and multifunctional arene ruthenium chemotherapeutics
Abstract
The introduction of multifunctionalities for tumour targeting is becoming a popular strategy toward the development of new therapeutic agents. In particular, the multifaceted potential of ruthenium(II)-arene complexes show great promise as chemotherapeutics. An ever-increasing number of papers dealing with the integration of ruthenium complexes with biologically active molecules to derive bioorganometallic molecules of chemotherapeutic significance have been published in recent years. This perspective review presents a short overview of multifunctional ruthenium-based drugs, especially those containing arene ruthenium complexes, with the emphasis on the combination of photosensitizers with ruthenium complexes for the preparation of novel multifunctional photodynamic therapy agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Maeda, H. (2001) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(00)00013-3 · Cited by 2,495
The role of porphyrin chemistry in tumor imaging and photodynamic therapy
Ethirajan, M., Chen, Y., Joshi, P., & Pandey, R. K. (2011) · Chem. Soc. Rev. · doi:10.1039/b915149b · Cited by 2,034
Organometallic Anticancer Compounds
Gasser, G., Ott, I., & Metzler-Nolte, N. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm100020w · Cited by 1,624
Ritchie, T. J., & Macdonald, S. J. F. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.07.014 · Cited by 901
Hartinger, C. G., Jakupec, M. A., Zorbas‐Seifried, S., Groessl, M., Egger, A., Berger, W., Zorbas, H., Dyson, P. J., & Keppler, B. K. (2008) · Chemistry & Biodiversity · doi:10.1002/cbdv.200890195 · Cited by 830
In Vitro and in Vivo Evaluation of Ruthenium(II)−Arene PTA Complexes
Scolaro, C., Bergamo, A., Brescacín, L., Delfino, R., Cocchietto, M., Laurenczy, G., Geldbach, T. J., Sava, G., & Dyson, P. J. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050015d · Cited by 784
Areneruthenium complexes as anticancer agents
Süß‐Fink, G. (2009) · Dalton Transactions · doi:10.1039/b916860p · Cited by 652
Recent developments in ruthenium anticancer drugs
Levina, A., Mitra, A., & Lay, P. A. (2009) · Metallomics · doi:10.1039/b904071d · Cited by 592
Hyperthermia adds to chemotherapy
Issels, R. D. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.07.038 · Cited by 545
Structure and Biodistribution Relationships of Photodynamic Sensitizers*
Boyle, R. W., & Dolphin, D. (1996) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.1996.tb03093.x · Cited by 498
Photoactivated chemotherapy (PACT): the potential of excited-state d-block metals in medicine
Farrer, N. J., Salassa, L., & Sadler, P. J. (2009) · Dalton Transactions · doi:10.1039/b917753a · Cited by 496
Therrien, B., Süss‐Fink, G., Govindaswamy, P., Renfrew, A. K., & Dyson, P. J. (2008) · Angewandte Chemie International Edition · doi:10.1002/anie.200800186 · Cited by 446
Self-citationOrganometallic ruthenium-based antitumor compounds with novel modes of action
Ang, W. H., Casini, A., Sava, G., & Dyson, P. J. (2011) · Journal of Organometallic Chemistry · doi:10.1016/j.jorganchem.2010.11.009 · Cited by 366
Developing new metal-based therapeutics: challenges and opportunities
Hambley, T. W. (2007) · Dalton Transactions · doi:10.1039/b706075k · Cited by 337
Hannon, M. J. (2007) · Pure and Applied Chemistry · doi:10.1351/pac200779122243 · Cited by 313
Targeting platinum anti-tumour drugs: Overview of strategies employed to reduce systemic toxicity
Zutphen, S. V., & Reedijk, J. (2005) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2005.03.005 · Cited by 295
Porphyrin‐related photosensitizers for cancer imaging and therapeutic applications
BERG, K., SELBO, P. K., WEYERGANG, A., DIETZE, A., PRASMICKAITE, L., BONSTED, A., ENGESAETER, B. Ø., ANGELL‐PETERSEN, E., WARLOE, T., FRANDSEN, N., et al. (2005) · Journal of Microscopy · doi:10.1111/j.1365-2818.2005.01471.x · Cited by 274
Control of tumour vascular permeability
Baban, D. F., & Seymour, L. W. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00003-9 · Cited by 237
Metal-based antitumour drugs in the post-genomic era: what comes next?
Sava, G., Bergamo, A., & Dyson, P. J. (2011) · Dalton Transactions · doi:10.1039/c1dt10522a · Cited by 231
Ruthenium Anticancer Compounds: Challenges and Expectations
Bratsos, I., Jedner, S., Gianferrara, T., & Alessio, E. (2007) · CHIMIA · doi:10.2533/chimia.2007.692 · Cited by 225
Development of Ruthenium Antitumor Drugs that Overcome Multidrug Resistance Mechanisms
Vock, C. A., Ang, W. H., Scolaro, C., Phillips, A. D., Lagopoulos, L., Juillerat-Jeanneret, L., Sava, G., Scopelliti, R., & Dyson, P. J. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070039f · Cited by 185
Rational Design of an Organometallic Glutathione Transferase Inhibitor
Ang, W. H., Parker, L. J., De Luca, A., Juillerat‐Jeanneret, L., Morton, C. J., Lo Bello, M., Parker, M. W., & Dyson, P. J. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200900185 · Cited by 182
Bioorganometallics: Future Trends in Drug Discovery, Analytical Chemistry, and Catalysis,
Hillard, E. A., & Jaouen, G. (2011) · Organometallics · doi:10.1021/om100964h · Cited by 178
Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339
Heffeter, P., Böck, K., Atil, B., Reza Hoda, M. A., Körner, W., Bartel, C., Jungwirth, U., Keppler, B. K., Micksche, M., Berger, W., et al. (2010) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-010-0642-1 · Cited by 173
Vančo, J., Marek, J., Trávníček, Z., Račanská, E., Muselík, J., & Švajlenová, O. (2008) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2007.10.003 · Cited by 168
Carbohydrate-Metal Complexes and their Potential as Anticancer Agents
Hartinger, C., Nazarov, A., Ashraf, S., Dyson, P., & Keppler, B. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708785908978 · Cited by 167
Collin, J., Harriman, A., Heitz, V., et al. (1994) · Journal of the American Chemical Society · doi:10.1021/ja00092a020 · Cited by 155
Transition Metal Based Anticancer Drugs
Garbutcheon‐Singh, K. B., Grant, M. P., Harper, B. W. J., Krause‐Heuer, A. M., Manohar, M., Orkey, N., & Aldrich-Wright, J. R. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611794785226 · Cited by 150
Auzias, M. G., Therrien, B., Süß‐Fink, G., Štěpnička, P., Ang, W. H., & Dyson, P. J. (2007) · Inorganic Chemistry · doi:10.1021/ic7018742 · Cited by 144
Self-citationFuture of Oncologic Photodynamic Therapy
Allison, R. R., Bagnato, V. S., & Sibata, C. H. (2010) · Future Oncology · doi:10.2217/fon.10.51 · Cited by 139
Hexanuclear self-assembled arene-ruthenium nano-prismatic cages: potential anticancer agents
Vajpayee, V., Yang, Y. J., Kang, S. C., Kim, H., Kim, I. S., Wang, M., Stang, P. J., & Chi, K. (2011) · Chemical Communications · doi:10.1039/c1cc10167f · Cited by 137
Ruthenium−Porphyrin Conjugates with Cytotoxic and Phototoxic Antitumor Activity
Gianferrara, T., Bergamo, A., Bratsos, I., Milani, B., Spagnul, C., Sava, G., & Alessio, E. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1002588 · Cited by 130
Evidence for Drug Release from a Metalla‐Cage Delivery Vector Following Cellular Internalisation
Zava, O., Mattsson, J., Therrien, B., & Dyson, P. J. (2009) · Chemistry - A European Journal · doi:10.1002/chem.200903216 · Cited by 127
Self-citationOrganometallic Ruthenium Inhibitors of Glutathione‐S‐Transferase P1‐1 as Anticancer Drugs
Ang, W. H., Luca, A. D., Chapuis‐Bernasconi, C., Juillerat‐Jeanneret, L., Bello, M. L., & Dyson, P. J. (2007) · ChemMedChem · doi:10.1002/cmdc.200700209 · Cited by 126
Boron neutron capture therapy at the crossroads: Challenges and opportunities
Barth, R. F. (2009) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2009.03.102 · Cited by 123
Combined arene ruthenium porphyrins as chemotherapeutics and photosensitizers for cancer therapy
Schmitt, F., Govindaswamy, P., Zava, O., Süß‐Fink, G., Juillerat‐Jeanneret, L., & Therrien, B. (2008) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-008-0427-y · Cited by 102
Self-citationRuthenium(II) Metallo‐intercalators: DNA Imaging and Cytotoxicity
Gill, M. R., Derrat, H. S., Smythe, C., Battaglia, G., & Thomas, J. A. (2011) · ChemBioChem · doi:10.1002/cbic.201000782 · Cited by 101
Pitto‐Barry, A., Barry, N. P. E., Zava, O., Deschenaux, R., Dyson, P. J., & Therrien, B. (2011) · Chemistry - A European Journal · doi:10.1002/chem.201002634 · Cited by 91
Self-citationAnticancer activity of opened arene ruthenium metalla-assemblies
Barry, N. P. E., Zava, O., Furrer, J., Dyson, P. J., & Therrien, B. (2010) · Dalton Transactions · doi:10.1039/c001521k · Cited by 82
Self-citationOrganometallic Antitumour Agents with Alternative Modes of Action
Casini, A., Hartinger, C. G., Nazarov, A. A., et al. (2010) · Topics in organometallic chemistry · doi:10.1007/978-3-642-13185-1_3 · Cited by 67
Pitto‐Barry, A., Barry, N. P. E., Zava, O., Deschenaux, R., & Therrien, B. (2011) · Chemistry - An Asian Journal · doi:10.1002/asia.201100136 · Cited by 65
Self-citationModulation of Photosensitization Processes for an Improved Targeted Photodynamic Therapy
Verhille, M., Couleaud, P., Vanderess, R., Brault, D., Barberi‐Heyob, M., & Frochot, C. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710793205453 · Cited by 63
Synthetic strategies towards ruthenium–porphyrin conjugates for anticancer activity
Gianferrara, T., Bratsos, I., Iengo, E., Milani, B., Ostric, A., Spagnul, C., Zangrando, E., & Alessio, E. (2009) · Dalton Transactions · doi:10.1039/b911393b · Cited by 62
Poon, C., Chan, P., Man, C., Jiang, F., Wong, R. N., Mak, N. K., Kwong, D. W. J., Tsao, S., & Wong, W. (2009) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2009.10.004 · Cited by 55
Inert ruthenium half-sandwich complexes with anticancer activity
Meggers, E., Atilla‐Gokcumen, G. E., Gründler, K., Frias, C., & Prokop, A. (2009) · Dalton Transactions · doi:10.1039/b917792b · Cited by 54
A bifunctional organometallic ruthenium drug with multiple modes of inducing apoptosis
Chatterjee, S., Biondi, I., Dyson, P. J., & Bhattacharyya, A. (2011) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-011-0772-0 · Cited by 49
Zinc tetraruthenated porphyrin binding and photoinduced oxidation of calf-thymus DNA
Araki, K., Silva, C. A., Toma, H. E., Catalani, L. H., de Medeiros, M. H. G., & Mascio, P. D. (2000) · Journal of Inorganic Biochemistry · doi:10.1016/s0162-0134(00)00053-2 · Cited by 47
Biersack, B., Zoldáková, M., Effenberger, K. E., & Schobert, R. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.01.040 · Cited by 45
Synthesis, Characterization and Anticancer Activity of Porphyrin-Containing Organometallic Cubes
Barry, N. P. E., Zava, O., Dyson, P. J., & Therrien, B. (2010) · Australian Journal of Chemistry · doi:10.1071/ch10221 · Cited by 45
Self-citationLiu, Y., Zhang, X., Zhang, R., Chen, T., Wong, Y., Liu, J., & Zheng, W. (2011) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.201000968 · Cited by 15
Cited by
Zeng, L., Gupta, P., Chen, Y., Wang, E., Ji, L., Chao, H., & Chen, Z.-S. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00195a · Cited by 1,017
Exploration of the medical periodic table: towards new targets
Barry, N. P. E., & Sadler, P. J. (2013) · Chemical Communications · doi:10.1039/c3cc41143e · Cited by 717
Combination of Ru(ii) complexes and light: new frontiers in cancer therapy
Mari, C., Pierroz, V., Ferrari, S., & Gasser, G. (2015) · Chemical Science · doi:10.1039/c4sc03759f · Cited by 570
The potential of organometallic complexes in medicinal chemistry
Gasser, G., & Metzler-Nolte, N. (2012) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2012.01.013 · Cited by 516
The development of RAPTA compounds for the treatment of tumors
Murray, B. S., Babak, M. V., Hartinger, C. G., & Dyson, P. J. (2016) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2015.06.014 · Cited by 455
Metadata
- Authors
- Smith, G. S., & Therrien, B.
- Venue
- Dalton Transactions
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2011
- Volume
- 40
- Issue
- 41
- Pages
- 10793
- ISSN
- 1477-9226 (ISSN-L)
- 1477-9234
- OpenAlex
- W2027840734
- Cited by
- 262
- References
- 51
- FWCI
- 13.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.